| pubmed-article:19738457 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19738457 | lifeskim:mentions | umls-concept:C0345967 | lld:lifeskim |
| pubmed-article:19738457 | lifeskim:mentions | umls-concept:C1511876 | lld:lifeskim |
| pubmed-article:19738457 | lifeskim:mentions | umls-concept:C0217540 | lld:lifeskim |
| pubmed-article:19738457 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:19738457 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:19738457 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19738457 | pubmed:dateCreated | 2009-10-28 | lld:pubmed |
| pubmed-article:19738457 | pubmed:abstractText | Tenascin XB (TNXB) was previously identified as a gene that is more highly expressed in malignant mesothelioma compared with ovarian/peritoneal serous carcinoma based on gene expression array analysis. The objective of this study was to validate this finding at the mRNA and protein levels. Effusions (n = 91; 71 ovarian carcinomas, 10 breast carcinomas, and 10 malignant mesotheliomas) were assayed for TNXB mRNA expression using quantitative polymerase chain reaction. Tenascin-X protein expression was studied in 183 effusions (137 carcinomas of different origin, 37 mesotheliomas, and 9 reactive effusions) and 178 solid lesions (122 ovarian/peritoneal carcinomas and 56 mesotheliomas) using immunohistochemistry. Quantitative polymerase chain reaction analysis showed significantly higher TNXB mRNA level in mesotheliomas compared with ovarian and breast carcinomas (P < 0.001). By immunohistochemistry, tenascin-X protein expression was significantly higher in malignant mesothelioma compared with metastatic carcinoma in effusions (34 of 37 vs. 31 of 137 positive cases; sensitivity = 92% and specificity = 77%; P < 0.001). Reactive mesothelial cells had focal or no tenascin-X expression. Tenascin-X protein was detected in 41 of 56 mesothelioma biopsy specimens and was uniformly absent from all 122 ovarian carcinomas (sensitivity = 73% and specificity = 100%; P < 0.001). Our data suggest that tenascin-X may be a new diagnostic marker of malignant mesothelioma in the differential diagnosis of cancers involving the serosal cavities, particularly in the differential diagnosis between this tumor and ovarian/peritoneal serous carcinoma. | lld:pubmed |
| pubmed-article:19738457 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19738457 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19738457 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19738457 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19738457 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19738457 | pubmed:issn | 1532-0979 | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:WuChuanyueC | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:NeslandJahn... | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:XXX | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:DavidsonBenB | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:BjørangOlaO | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:StavnesHelene... | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:NymoenDag... | lld:pubmed |
| pubmed-article:19738457 | pubmed:author | pubmed-author:RosnesAnne... | lld:pubmed |
| pubmed-article:19738457 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19738457 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:19738457 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19738457 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19738457 | pubmed:pagination | 1673-82 | lld:pubmed |
| pubmed-article:19738457 | pubmed:dateRevised | 2011-9-16 | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:meshHeading | pubmed-meshheading:19738457... | lld:pubmed |
| pubmed-article:19738457 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19738457 | pubmed:articleTitle | Tenascin-X is a novel diagnostic marker of malignant mesothelioma. | lld:pubmed |
| pubmed-article:19738457 | pubmed:affiliation | Department of Pathology, Norwegian Radium Hospital, Norway. | lld:pubmed |
| pubmed-article:19738457 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19738457 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19738457 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:7148 | entrezgene:pubmed | pubmed-article:19738457 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19738457 | lld:entrezgene |
